GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis

Elsa Vieira-Sousa, Pedro Alves, Ana M. Rodrigues, Filipa Teixeira, Jose Tavares-Costa, Alexandra Bernardo, Sofia Pimenta, Fernando M. Pimentel-Santos, João Lagoas Gomes, Renata Aguiar, Patrícia Pinto, Taciana Videira, Cristina Catita, Helena Santos, Joana Borges, Graça Sequeira, Célia Ribeiro, Lídia Teixeira, Pedro Ávila-Ribeiro, Fernando M. MartinsHelena Canhão, Iain B. McInnes, Ruy M. Ribeiro, João Eurico Fonseca

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Fingerprint

Dive into the research topics of 'GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry